These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 27646775)
1. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775 [TBL] [Abstract][Full Text] [Related]
2. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872 [TBL] [Abstract][Full Text] [Related]
3. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420 [TBL] [Abstract][Full Text] [Related]
4. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840 [TBL] [Abstract][Full Text] [Related]
5. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
6. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881 [TBL] [Abstract][Full Text] [Related]
8. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930 [TBL] [Abstract][Full Text] [Related]
9. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821 [TBL] [Abstract][Full Text] [Related]
10. The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression. Fontana V; Vigani A; Pistillo MP; Giannoni U; Rosemberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S J Thorac Oncol; 2019 May; 14(5):e92-e94. PubMed ID: 31027749 [No Abstract] [Full Text] [Related]
11. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568 [TBL] [Abstract][Full Text] [Related]
12. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma. Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917 [TBL] [Abstract][Full Text] [Related]
13. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138 [TBL] [Abstract][Full Text] [Related]
14. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145 [TBL] [Abstract][Full Text] [Related]
15. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362 [TBL] [Abstract][Full Text] [Related]
16. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302 [TBL] [Abstract][Full Text] [Related]
17. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128 [TBL] [Abstract][Full Text] [Related]
18. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044 [TBL] [Abstract][Full Text] [Related]
19. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. Wheatley-Price P; Yang B; Patsios D; Patel D; Ma C; Xu W; Leighl N; Feld R; Cho BC; O'Sullivan B; Roberts H; Tsao MS; Tammemagi M; Anraku M; Chen Z; de Perrot M; Liu G J Clin Oncol; 2010 Jul; 28(20):3316-22. PubMed ID: 20498407 [TBL] [Abstract][Full Text] [Related]
20. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos. Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M Oncology; 2014; 86(1):33-43. PubMed ID: 24401539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]